Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
142.74
-1.75 (-1.21%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
49
50
Next >
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
May 01, 2024
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Profit from the Panic: 3 Stocks to Pounce on When They Become Steals
May 01, 2024
We love it when our favorite clothes go on sale, so when the market offers us a deal, these are the stocks to buy on dips.
Via
InvestorPlace
Moody’s, Booking, DraftKings, Amgen Stocks In Focus Ahead Of Earnings
May 01, 2024
American stocks were mixed on Wednesday as the earnings season continued and as investors waited for the latest Federal Reserve decision. The Dow Jones rose by over 65 points while the S&P 500 and...
Via
Talk Markets
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Consumer Stocks.
May 01, 2024
While some retail companies are still thriving, investors would be smart to steer clear of these consumer stocks to avoid.
Via
InvestorPlace
Analyzing NYSE:NVO's Dividend Potential.
April 30, 2024
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) provides a good dividend, while having solid fundamentals.
Via
Chartmill
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
April 29, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
April 26, 2024
Via
Benzinga
Setback For Novo Nordisk? Denmark Shifts Prescription Guidelines, Favoring Cost-Effective Alternatives For Ozempic
May 01, 2024
The agency noted that in 2023, half of the new type 2 diabetes patients started their treatment with a reimbursed GLP-1 drug without trying a cheaper alternative first.
Via
Benzinga
How Consumer Demand Is Impacting Taiwan Semiconductor Manufacturing Co.
May 01, 2024
We also look at the "treasure hunt" economy.
Via
The Motley Fool
3 of Europe’s ‘Magnificent 18’ Stocks That You Can Buy in the U.S.
April 30, 2024
The Magnificent Seven is so yesterday. The new trend is to invest in some of the top European stocks, dubbed the Magnificent 18.
Via
InvestorPlace
Eli Lilly Stock Jumps On Strong Earnings, Guidance As Zepbound Sales Easily Beat
April 30, 2024
Overall revenue fell short in Q1. Lilly stock is set to cross a key level.
Via
Investor's Business Daily
Billionaire Investor Jim Simons Just Bought These 3 "Magnificent Seven" Stocks
April 29, 2024
The "Magnificent Seven" stocks dominate the artificial intelligence (AI) arena. One notable hedge fund manager has three in his top 10 holdings.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) a Strong Candidate for Quality Investing?
April 25, 2024
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) qualifies as a quality stock.
Via
Chartmill
Why Novo Nordisk Topped the Market Today
April 22, 2024
It's not only spending its capital on developing new drugs.
Via
The Motley Fool
Is Viking Therapeutics Incredibly Undervalued?
April 28, 2024
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
Via
The Motley Fool
Forget Nvidia, These Unstoppable Stocks Are Better Buys
April 27, 2024
These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence.
Via
The Motley Fool
1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On
April 27, 2024
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.
Via
The Motley Fool
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
April 24, 2024
Senate Committee probes Novo Nordisk's pricing tactics for diabetes and obesity meds. Sanders demands transparency on pricing, signaling broader industry scrutiny. Medicare coverage expansion could...
Via
Benzinga
3 Biotech Stocks With Skyrocketing Potential: April 2024
April 24, 2024
These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time.
Via
InvestorPlace
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
April 24, 2024
Lilly recently announced news that could solve a big problem.
Via
The Motley Fool
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
April 24, 2024
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.
Via
InvestorPlace
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
April 24, 2024
Good news could be just around the corner for two drugmakers not named Novo Nordisk.
Via
The Motley Fool
Better Buy: Pfizer vs. Viking Therapeutics
April 23, 2024
These two pharma stocks have followed distinct paths of late. Which is the better investment?
Via
The Motley Fool
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
April 23, 2024
These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth.
Via
InvestorPlace
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
April 22, 2024
Discover how GLP-1 drugs reshape consumer spending in food industries. Novo Nordisk's Wegvoy and Eli Lilly's Zepbound gain traction, altering dining habits.
Via
Benzinga
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
April 20, 2024
These stocks probably won't be getting much cheaper.
Via
The Motley Fool
3 Relatively Safe Growth Stocks You Can Buy and Hold
April 20, 2024
Low risk and high-reward potential? These stocks could offer both.
Via
The Motley Fool
3 Biotech Stocks Set to Double by 2028
April 20, 2024
These are three of the top biotech stocks set to double by 2028. Add them to your portfolio to maximize your potential gains.
Via
InvestorPlace
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
April 19, 2024
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.
Via
The Motley Fool
German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline
April 18, 2024
Novo Nordisk's acquisition of Cardior Pharmaceuticals clears regulatory hurdles, advancing cardiovascular treatment development with CDR132L. Learn about the promising phase 2 trials and strategic...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
49
50
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.